BACKGROUNDSince 2001, newborn hearing screening has been performed in Japan.OBJECTIVEThis study compared newborn hearing screening results between the MAICO MB11 BERAphone (MB11) and the Natus ALGO2e color (ALGO) Automated Auditory Brainstem Response (AABR) devices among healthy Japanese newborns.MATERIALS AND METHODSFrom December 2014 to April 2018, 1477 healthy newborns were screened by MB11 and 267 by ALGO. Data from at-risk newborns were not included. Outcomes were 'Pass' and 'Refer' rates, specificity, false-positive rates, and assessment duration. Infants with a Refer result were examined using Interacoustics Eclipse.RESULTSMB11 identified 1425 (96.5%) as Pass and 52 (3.5%) as Refer. ALGO identified 263 (98.5%) as Pass and four (1.5%) as Refer. Specificity and false-positive rates were 97.7% and 2.3% for MB11 and 98.5% and 1.5% for ALGO, respectively. Using MB11, the total mean assessment time was 320.2 ± 220.7 s, with 315.6 ± 214.2 s for Pass and 628.6 ± 288.8 s for Refer.CONCLUSIONSMB11 is useful for hearing screening in healthy Japanese newborns and is fast and easy to operate. MB11 showed high specificity equivalent to ALGO.

01 Aug 1985·Clinical and experimental immunologyQ3 · MEDICINE

Common epitopes between mycobacterial and certain host tissue antigens.

Q3 · MEDICINE

Article

Author: Thorns, C J ; Morris, J A

Monoclonal antibodies (MoAb) produced against a sonicated antigen extract of Mycobacterium bovis were examined for their ability to bind to 10 common tissue antigens. The binding patterns of MoAb MB2, MB3, MB7, MB11 and MB13 indicated that each recognized different epitopes. MoAb MB5 and MB17 failed to bind to any of the tissue antigens. MB3 reacted strongly with normal tissue from M. bovis infected guinea pigs and ferrets but there was no reaction with MB5 and MB17. These specificities were confirmed by reciprocal absorption experiments. It is concluded that Mycobacterium species contain epitopes that are also present in host tissue antigens.

100 Deals associated with MB-11

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Tuberculosis	Preclinical	US	Microbion Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

MB-11

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation